A study of acute respiratory disease in horses in Ontario was undertaken to determine the identity of current causative infectious agents. A nasopharyngeal swab was designed and utilized to maximize isolation of viruses, mycoplasma, and pathogenic bacteria. Serum samples were collected for parallel determination of antibody titers to equine influenza virus type A subtype 1 (H7N7) and subtype 2 (H3N8), equine rhinovirus types 1 and 2, equine herpesvirus type 1, Mycoplasma equirhinius, and Mycoplasma felis. Equine rhinovirus type 2 was recovered from 28/92 horses tested, and equine influenza virus type A, subtype 2, was recovered from 5. The mycoplasma and bacteria isolated were consistent with those commonly associated with nonspecific respiratory diseases in horses, except that Streptococcus pneumoniae capsular type 3 was isolated from 10 horses.
Abstract.
A study of acute respiratory disease in horses in Ontario was undertaken to determine the identity of current causative infectious agents. A nasopharyngeal swab was designed and utilized to maximize isolation of viruses, mycoplasma, and pathogenic bacteria. Serum samples were collected for parallel determination of antibody titers to equine influenza virus type A subtype 1 (H7N7) and subtype 2 (H3N8), equine rhinovirus types 1 and 2, equine herpesvirus type 1, Mycoplasma equirhinius, and Mycoplasma felis. Equine rhinovirus type 2 was recovered from 28/92 horses tested, and equine influenza virus type A, subtype 2, was recovered from 5. The mycoplasma and bacteria isolated were consistent with those commonly associated with nonspecific respiratory diseases in horses, except that Streptococcus pneumoniae capsular type 3 was isolated from 10 horses.
Contagious respiratory infections in horses are major causes of both acute and chronic respiratory diseases resulting in impaired pulmonary function and reduced performance. 12, 13, 39 The chronic sequelae are important to the horse industry and include bronchopneumonia, chronic obstructive pulmonary disease, and exerciseinduced hemorrhage. 26, 39 Earlier studies conducted in Ontario on thoroughbred 8 and standardbred horses used isolation and serodiagnosis to demonstrate that equine influenza virus type A subtypes 1 (AE1; H7N7) and 2 (AE2; H3N8), equine rhinovirus types 1 (ERhV-1) and 2 (ERhV-2), and equine rhinopneumonitis virus, now termed equine herpesvirus type 4 (EHV-4), were the major causes of respiratory disease. Other infectious agents that can induce respiratory disease in the horse are equine abortion virus 1 (distinguished as equine herpesvirus type 1 [EHV-1] 33 ), equine cytomegalovirus (equine herpesvirus type 2 10 ), equine arteritis virus (EAV), 34 equine adenovirus, 14,26 equine rhinovirus-3, 26 mycoplasmas, 16,40 and bacteria. 18,22 Vaccines are currently available in Ontario only for AE1, AE2, EHV-1, EHV-4, and EAV. These viral agents are believed to be the most common causes of clinical respiratory disease in North America. 26 However, acute respiratory disease continues to occur, despite judi-cious vaccination for AE1, 39 AE2, 39 EHV-1 , 24 and EHV-4 24 using modern vaccines. This continuing disease problem may be due to partial vaccine-induced immunity, genetic diversity of 26 or the antigenic drift of influenza viruses. 13, 26, 39 This study was conducted to identify the infectious agents more recently implicated in respiratory disease in horses in Ontario . 37 We used patient data, clinical examination, isolation, and paired serology for specific infectious agents. Nasal swabs from 92 horses with acute clinical respiratory disease from 29 different premises were cultured for viruses, mycoplasma, and pathogenic bacteria. Paired sera were collected and tested for antibodies to AE1, AE2, ERhV-1, ERhV-2, and EHV-1. For an additional 89 horses from 13 stables where respiratory disease occurred annually, these same serologic tests and antibody tests for EAV were performed.
Materials and methods

Horses
Letters describing the objectives of the study were mailed to equine veterinary practitioners in Ontario in the fall of 1987. Attending veterinarians were asked to notify the Equine Research Centre of stables experiencing either acute clinical respiratory disease, in which two or more horses in the same stable became ill, or recurring respiratory disorders, where respiratory disease occurred annually.
Visits and observations
Acute clinical respiratory disease. Premises were visited as soon as possible after notification (day 0) and on two subsequent occasions (days 14 and 28). At the initial visit, individual patient data, clinical history, and vaccination status were recorded, and clinical examination was performed.
The following were noted: rectal temperature, nasal/nasolachrymal discharge, submandibular lymph node enlargement, tracheal and laryngeal sensitivity to compression, classification of breathing, respiratory rate, and sounds from auscultation of the lung area. Nasopharyngeal swabs were collected at the first visit. Blood samples were collected at each of the three visits for use in serologic assays for AE1, AE2, ERhV-1, ERhV-2, EHV-1, Mycoplasma equirhinis, and M. felis.
Recurring respiratory disorders. Two visits 1 mo apart were made to each stable where the attending veterinarian reported annually recurring respiratory disorders. Clinical histories were obtained along with blood samples for serum antibody determinations.
Nasopharyngeal swabs
A sterile 1.5-cm (external diameter) polypropylene sleeve 55-60 cm in length was passed into the nasopharyngeal area via the ventral meatus. The introduced end of the sleeve was constructed to create a fold-over flap. An encased cylindrical sterile cotton swab was attached with surgical sutures by its center to create a "T" shape at one end of a 0.5-cm (external diameter) sterile 85-cm-long polyethylene tube. When the sleeve end reached the nasopharyngeal area, the cotton swab was pushed out and, while being held against the wall of the pharynx, rotated several times to obtain the sample. The swab was then retracted into the sleeve and withdrawn from the horse. The sleeve was held in place to permit insertion and collection of a second swab. The two swabs from each horse were immediately divided in half, and the resulting four sections were placed into separate 5-ml vials containing sterile antibiotic-free transport medium consisting of Hanks' balanced salt solution with 0.5% lactalbumin hydrolysate medium. Three of the four vials were placed in holders on aluminum canes and rapidly frozen in a portable liquid nitrogen tank for storage and transport to the laboratories. The fourth vial was protected from excess cold or heat and submitted for bacterial culture.
Virus isolation
Equine dermis (ED) and LLC-MK2 (derivative) cells a were maintained in minimum essential medium with Earle's salts b with 1% nonessential amino acids. c Rabbit kidney 13 (RK-13) cells d were sustained in minimum essential medium with Hanks' salts. a Medium for cell growth was supplemented with 10% unheated irradiated fetal bovine serum. e For virus isolation, medium for cell maintenance was augmented with 2% heat-treated irradiated serum. Cells and sera were free of mycoplasma and bovine viral diarrhea virus.
Nasopharyngeal swabs in transport media were maintained at or below -70 C. Each sample was thawed, and the medium was filtered using a 450-nm pore size filter f prior to being inoculated onto decanted partially confluent ED, LLC-MK2, and RK-13 cell monolayers established 24 hr earlier in borosilicate glass tissue culture tubes. After absorption for 1 hr at room temperature, cells were refed with maintenance media and incubated at 37 C for 7 days. Each cell culture was examined daily for cytopathic change. All cell cultures were passaged twice prior to being considered negative.
For the identification of virus isolates, cell cultures showing cytopathic effects were frozen and reinoculated onto matched cells grown in 25-cm 2 plastic flasks. When the cell monolayers were destroyed, they were frozen and used to determine the physiochemical characteristics of the virus isolates. Infected materials were examined with an electron microscope after centrifuging supernatant fluids at 10,000 x g for 1 hr. Resulting pelleted cellular material was mixed with distilled water and negatively stained using 2% phosphotungstic acid with 0.01% bovine serum albumin (pH 6.5). Grids were examined for virus particles using a transmission electron microscope. To determine the size of particles, supernatant fluids were filtered through 100-and 50-nm pore size filters f and reinoculated onto the corresponding cell line. To assess the presence of an envelope, supernatant fluids were shaken with chloroform for 10 min at room temperature. The mixture was centrifuged at 50 x g for 5 min, and the resulting uppermost layer was used for virus assay. Isolates characterized as rhinoviruses on the basis of physicochemical properties 21 were classified using type-specific antisera for ERhV-1 g and ERhV-2 g in mictrotiter virus neutralization (VN) assays. Each filtrate was also inoculated into 9-11-day-old specific-pathogen-free embryonated chicken eggs h in attempts to recover influenza viruses. Eggs were candled daily to detect embryo death. All specimens were passaged 3 times in eggs prior to being considered negative. At each weekly passage, allantoic fluids from inoculated embryonated eggs were tested using both guinea pig and chicken 0.5% red blood cell suspensions to identify hemagglutinin. Fluids that contained hemagglutinin were subtyped using hemagglutinin inhibition assays with specific turkey antisera to AE1 and AE2. Four hemagglutinating (HA) units of test and control isolates were used.
Viral serology
The sera from the clotted blood samples were separated and divided into aliquots and stored at -20 C. Virus neutralization tests were conducted to determine antibody responses for ERhV-1, g ERhV-2, g EHV-1, i and EAV. i Because EHV-1 and EHV-4 are antigenically indistinguishable without the aid of monoclonal antibodies 41 only EHV-1 was used as antigen in VN assays. All of the VN tests were conducted in the same manner using 96-well microtiter plates. Following serial 2-fold dilutions of the heat-inactivated sera, approximately 100 TCID 50 of the appropriate virus was added to each well. For the EAV VN assay, guinea pig complement at a final concentration of 10% was added with the challenge dose of virus. After a 1-hr incubation at 37 C, RK-13 cells were added, and the plates were incubated at 37 C in a 5% CO 2 atmosphere. Plates were read when control cultures showed extensive cytopathic effects.
For the measurement of antibody responses to equine influenza, hemagglutination inhibition (HI) assays were employed. The sera were treated with potassium periodate (final concentration of 0.25%) for 15 min at room temperature. The periodate was quenched with the addition of glycerol (final concentration of 0.75%). Serial 2-fold dilutions of the treated sera were made in V-bottom microtiter plates. To each well was added 4-8 HA units of either native virus AE1 (A/equine1/Prague/1/56) i or Tween 80/ether-treated virus AE2 (A/equine2/Miami/1/63). i
Mycoplasma culture and serology
The swabs were streaked onto medium as previously described 9 and suspended in semisolid medium for blind enrichment. Plates were streaked after 3 and 6 days incubation of the enrichment medium. The plates were incubated at 37 C in 5% CO 2 for 8 days and checked for mycoplasma growth. Selected colonies were purified by subculture and identified on the basis of biochemical reactivity 9 and fluorescent antibody staining using reference sera. j,29 Antibody to Mycoplasma felis, strain D120, and M. equirhinis, strain K32C, were determined using the indirect hemagglutination (IHA) test. 6 Significant changes in antibody titers to the various viral and mycoplasma organisms investigated were defined as seroconversion (negative to positive) or a 4-fold (or greater) rise in antibody response between paired sera.
Bacterial culture
Swabs were streaked on blood agar and MacConkey agar plates, which were then incubated at 37 C. The blood agar plates were incubated in an atmosphere enhanced with 5% CO 2 . All plates were examined after 18 and 42 hr of incubation. Subcultures were made when necessary, and tests were carried out to identify the various types of colonies on the plates. Identification was based on standard procedures. 5 Colony characteristics on blood and MacConkey agar plates, appearance in Gram-stained smears, and reactions in biochemical tests were used. Alpha-hemolytic streptococci were tested for bile solubility and susceptibility to optochin to detect Streptococcus pneumoniae. Beta-hemolytic streptococci were tested for utilization of trehalose and Sorbitol to distinguish among S. equi ssp. zooepidemicus and S. equi ssp. equi. Additional biochemical reactions for identification included tests for cytochrome oxidase, oxidation/fermentation, coagulase, catalase, urease, and production of indole from tryptophan.
Results
Acute clinical respiratory disease. Acute clinical respiratory disease was investigated at 29 different locations between December 1987 and July 1988. Nasopharyngeal swabs and paired blood samples were collected from 92 horses. The ages of the horses ranged from 1 to 16 years; 43% of the horses were ≤ 2 years of age. Standardbred and thoroughbred breeds represented the majority (42% and 40%, respectively). Forty-two percent were female, 31% were stallions, and 24% were geldings. Sixty-four percent were racing or in training, 22% were inactive (broodmares, young, lameness recuperation), 9% were pleasure horses, and 5% were working draft horses. Forty-eight percent had been moved from 1 location to another in the 3 months prior to the initial visit.
The clinical signs (percentage of horses affected) at Table 1 . Number of horses with acute respiratory disease from which infectious agents were isolated and that showed significant changes in antibody titers* to viral and mycoplasma agents (n = 92 total affected horses). the larynx (7%), and abnormal breathing (1%). Fortyseven percent of the horses had been treated before the clinical examinations. In general, clinical disease in these horses was relatively mild; at initial examination, the 3 main clinical signs (cough, fever, nasal discharge) traditionally associated with acute respiratory disease were present together in only 15% of the affected horses in this study. As expected, it was not possible to predict the etiologic agent that would be recovered from horses with clinical respiratory disease on the basis of history and clinical examination alone.
Forty-three percent of the horses had been vaccinated against equine influenza within the past 12 months, 29% against equine herpes, and 8% against equine encephalitis viruses. Approximately 40% of the horses were known not to have received these vaccines, the time of initial examination were cough (52%), fever and the remaining had unknown vaccination status. (48%), increased nasal discharge (65%), lymph node
The number of horses from which viruses and myenlargement (13%), increased lachrymal discharge coplasmas were isolated and that demonstrated a sig-(15%), abnormal response to digital compression of nificant change in antibody titer are given in Table 1 . Previous vaccination could not be correlated to lack of clinical disease. The isolates (percentage of affected horses) were AE2 (5.4%), ERhV-2 (30.4%), Mycoplasma equirhinis (59.8%), and M. felis (6.5%). Horses from which AE2 was recovered demonstrated relatively more severe clinical disease.
The most frequently isolated bacteria were a-hemolytic streptococci, nonhemolytic staphylococci, Streptococcus equi ssp. zooepidemicus, and Actinobacillus sp. (Table 2 ). An a-hemolytic streptococcus cultured under an enhanced CO 2 environment and subsequently typed as S. pneumoniae capsular type 3 was isolated from 10 horses stabled at a racetrack. This microorganism was frequently isolated in conjunction with other streptococci, Flavobacterium, and M. equirhinis.
Recurring respiratory disorders. Paired serum samples were collected from an additional 89 horses of various breeds from 13 stables with annually recurring respiratory disorders. Although clinical disease was not noted, horses had significant changes in antibody titers to viral agents (Table 3) .
Discussion
Because severity of acute viral respiratory disease and duration of signs depend on the virulence of the virus strain, dose, management, environmental conditions, and host defenses, 39 the relatively mild clinical signs seen in most horses in this study may have been related to the moderate winter that occurred over the course of the study or to infection with agents that cause only mild disease. Alternatively, the less severe clinical disease may have been a result of partial immunity due to previous infection or vaccination. 24, 39 Horses that have been recently and regularly vaccinated may be subclinically infected during outbreaks of herpesvirus 13 or influenza. 39 Table 3 . Number of horses from stables reporting recurring acute respiratory diseases with and without significant changes in antibody titers* to viral agents (n = 92 total affected horses).
Even though respiratory infections are a major concern in the horse industry, only about half the horses in this study had been vaccinated for influenza, and even fewer had been vaccinated for herpesvirus. For those that were vaccinated, the administration of vaccines did not appear to be related to the expression of clinical disease, the recovery of specific infectious agents, or subsequent antibody responses. These findings suggest either that vaccine immunity was incomplete or that other infectious agents were involved.
The large numbers of ERhV-2 isolates recovered from 30.4% of horses with acute respiratory disease in this study suggests that ERhV-2 may play an important role in acute clinical respiratory infections in horses in Ontario. Equine rhinoviruses are picornaviruses, which spread readily by direct and indirect contact with nasal secretions or by aerosol inhalation. 3 They are resistant to environmental extremes and therefore readily contaminate an environment. 3 Rhinoviruses replicate in the upper respiratory tract, with viremia occurring 3-7 days after exposure. Viremia, but not always nasopharyngeal virus shedding, is terminated in 4-5 days with the appearance of neutralizing antibody. 3 Clinical signs can range from severe pharyngitis with pyrexia and serous or mucopurulent nasal discharge 2,7,25 to transient pyrexia, with mild 36 or no 38 clinical signs. Virus may be isolated from nasal swabs of clinically ill animals for 1 month after infection and from clinically healthy horses with high antibody titers. 25, 26 Others have reported that equine rhinoviruses may be recovered from clinically normal carrier horses for up to 18 months. 2, 21 The etiopathologic role of equine rhinoviruses may range from being the only infectious agent isolated from horses with mild respiratory signs to altering local host defence mechanisms and enabling other agents to become more invasive, aggressive, and pathogenic. 2, 7, 11, 15, 17, 9, 21, 25, 27, 28 Isolation of rhinoviruses has often been associated with clinical outbreaks of equine herpesvirus and EAV. 5, 26 Of the 28 horses from which ERhV-2 was recovered, a serologic diagnosis of ERhV-2 infection was asso-ciated with only 6 horses. Significant change in antibody titers for paired sera could not be demonstrated for 75% of the horses from which ERhV-2 was recovered. Attempts to demonstrate a rise in serum antibody titer to rhinovirus are commonly unsuccessful 26 perhaps because antibody levels rises rapidly from day 6 to peak between days 14 and 18, making it difficult to collect acute samples early enough to be able to demonstrate significant changes. 26 Although ERhV-1 was not recovered from any horse, 9 horses had significant changes in antibody titer to this virus, suggesting that it was also a cause of acute respiratory infections in these horses.
Even though equine influenza viruses are shed for as long as 8-12 days, 39 these viruses are only readily isolated during the first 24-48 hours after the onset of illness 28 Horses that no longer show an elevated body temperature are not good candidates for virus recovery, 26 which may be why AE2 was recovered from only 5 horses in this study even though 23.6% had significant changes in antibody to this antigen. More horses were infected with AE2 than is indicated by virus recovery. The increased severity in clinical disease seen in the 5 horses from which AE2 was recovered may be a result of primary infection with this agent; naive animals are more likely to be severely clinically affected, shed more virus for longer periods, and be successful sources for virus recovery. 26, 39 Clinical disease due to AE2, which has greater antigenic drift 39 and greater tendency to invade the lower respiratory tract, 26 is usually more severe than that due to AE1. 26 The stress of training also can exacerbate clinical disease. 39 Because horses are immune to influenza virus for about 12 months after infection or 3-4 months after vaccination, 26 the equine population contains many partially immune horses (vaccinated or recovered) that may experience reduced virus shedding, with mild or no clinical signs . 26, 39 Some of these subclinically infected horses shed virus without developing a 4-fold significant rise in antibody titer, such that the HI test may fail to identify infected horses. 39 Serologic tests will not detect subclinical infections that are not accompanied by seroconversion. 39 Even though AE1 was not recovered from horses in this study, 17 (18.5%) had significant 4-fold changes in antibody titer to AE1. This finding is consistent with previous reports that although AE1 has not been recovered from horses since 1980 unvaccinated horses still have antibodies, suggesting spread in subclinical form. 35, 39 The serology data indicate that 21.7% of horses in this study seroconverted to either EHV-1 or the antigenically related EHV-4. The absence of recovery of EHV-1 or EHV-4 isolates was unexpected given that the cell lines used are known to be susceptible to equine herpesviruses . 4 Immunity after infection or vaccination is short lived (3-5 months), 1,26 and these 2 viruses are expected to commonly induce clinical respiratory disease in horse popu1ations. 1 Studies conducted with EHV-1 indicate that the virus can usually be recovered for only a few days at the time of pyrexia during clinical illness, 27 even though virus shedding from the nasal passages may occur for up to 2-3 weeks postinfection, and latency is an important factor in viral pathogenesis. 1 Because specimens for virus isolation were frozen in liquid nitrogen immediately after collection, the lack of recovery of EHV-1 isolates probably is due to short and inconsistant virus shedding from the nasopharynx from partially immune animals rather than to problems in the transportation and processing of specimens in the laboratory.
A high prevalence of M. equirhinis isolates and serum antibody titers have been reported in horses, 23 yet the role this agent plays in respiratory disease is unknown. In this study, 2 of 6 horses (33.3%) with positive cultures for M. felis seroconverted to this organism, whereas only 8.7% of those horses without positive M. felis cultures seroconverted. This agent has previously been isolated from horses with pleuritis, and both natural and experimental cases have been shown to seroconvert. 30 Further evidence of the pathogenic potential of M. felis was recently provided when this organism was associated with lower respiratory tract disease among young race horses in training. 40 The bacteria isolated were similar to those that have been isolated from the upper airways of horses as indicated by the records of the Clinical Bacteriology Laboratory of the Veterinary Teaching Hospital, Ontario Veterinary College. The human pathogen Streptococcus pneumoniae capsular type 3 was isolated from 10 animals, but it was not evident that the infection had been preceded by viral infections, as previously suggested. 20 Although there were no respiratory outbreaks in horses from 13 stables with historical annual respiratory disease, the antibody titers on paired sera suggest that the same viruses involved in outbreaks of acute clinical respiratory disease (AE1, AE2, ERhV-2) are also important etiologic agents in stables with records of recurrent annual respiratory infections.
Although the prevalence of EAV antibody in Ontario in 1989 was 95% in standardbreds and 6.5% in thoroughbreds (data not shown), as similarly reported for other localities, 26 only 1 horse showed significant changes in antibody titer to EAV, which occurred without obvious clinical disease, as is the case for most EAV infections. 26 There are numerous viral, mycoplasma, and bacterial infectious agents still implicated in equine respiratory infection in horses in Ontario. However, the results of this study strongly suggest that ERhV-2 should be considered an important cause of acute viral respiratory infection and disease in horse populations in Ontario.
